1
|
Perera Y, Toro ND, Gorovaya L,
Fernandez-DE-Cossio J, Farina HG and Perea SE: Synergistic
interactions of the anti-casein kinase 2 CIGB-300 peptide and
chemotherapeutic agents in lung and cervical preclinical cancer
models. Mol Clin Oncol. 2:935–944. 2014.PubMed/NCBI
|
2
|
Huang Y, Li W, Wang CC, Wu X and Zheng J:
Cryptotanshinone reverses ovarian insulin resistance in mice
through activation of insulin signaling and the regulation of
glucose transporters and hormone synthesizing enzymes. Fertil
Steril. 102:589–596.e4. 2014. View Article : Google Scholar : PubMed/NCBI
|
3
|
Makris N, Edgren M, Mavroidis P and Lind
BK: Investigation of the dose- and time-dependence of the induction
of different types of cell death in a small cell lung cancer cell
line: Implementation of the repairable-conditionally repairable
model. Int J Oncol. 42:2019–2027. 2013.PubMed/NCBI
|
4
|
Wang F, Xu J, Zhu Q, Qin X, Cao Y, Lou J,
Xu Y, Ke X, Li Q, Xie E, et al: Downregulation of IFNG in CD4(+) T
cells in lung cancer through hypermethylation: A possible mechanism
of tumor-induced immunosuppression. PLoS One. 8:e790642013.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Wang YY, He XY, Cai YY, Wang ZJ and Lu SH:
The variation of CD4+CD25+ regulatory T cells in the periphery
blood and tumor microenvironment of non-small cell lung cancer
patients and the downregulation effects induced by CpG ODN. Target
Oncol. 6:147–154. 2011. View Article : Google Scholar : PubMed/NCBI
|
6
|
Wang W, Hodkinson P, McLaren F, MacKinnon
A, Wallace W, Howie S and Sethi T: Small cell lung cancer tumour
cells induce regulatory T lymphocytes and patient survival
correlates negatively with FOXP3+ cells in tumour infiltrate. Int J
Cancer. 131:E928–E937. 2012. View Article : Google Scholar : PubMed/NCBI
|
7
|
Yin HQ, Choi YJ, Kim YC, Sohn DH, Ryu SY
and Lee BH: Salvia miltiorrhiza Bunge and its active component
cryptotanshinone protects primary cultured rat hepatocytes from
acute ethanol-induced cytotoxicity and fatty infiltration. Food
Chem Toxicol. 47:98–103. 2009. View Article : Google Scholar : PubMed/NCBI
|
8
|
Pan Y, Bi HC, Zhong GP, Chen X, Zuo Z,
Zhao LZ, Gu LQ, Liu PQ, Huang ZY, Zhou SF and Huang M:
Pharmacokinetic characterization of
hydroxylpropyl-beta-cyclodextrin-included complex of
cryptotanshinone, an investigational cardiovascular drug purified
from Danshen (Salvia miltiorrhiza). Xenobiotica. 38:382–398. 2008.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Dai H, Wang M, Li X, Wang L, Li Y and Xue
M: Structural elucidation of in vitro and in vivo metabolites of
cryptotanshinone by HPLC-DAD-ESI-MS(n). J Pharm Biomed Anal.
48:885–896. 2008. View Article : Google Scholar : PubMed/NCBI
|
10
|
Cha JD, Lee JH, Choi KM, Choi SM and Park
JH: Synergistic effect between cryptotanshinone and antibiotics
against clinic methicillin and vancomycin-resistant staphylococcus
aureus. Evid Based Complement Alternat Med. 2014:4505722014.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Tang Y, Chen Y, Chu Z, Yan B and Xu L:
Protective effect of cryptotanshinone on lipopolysaccharide-induced
acute lung injury in mice. Eur J Pharmacol. 723:494–500. 2014.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Siemianowicz K, Gminski J, Stajszczyk M,
Wojakowski W, Goss M, Machalski M, Telega A, Brulinski K and
Magiera-Molendowska H: Serum HDL cholesterol concentration in
patients with squamous cell and small cell lung cancer. Int J Mol
Med. 6:307–311. 2000.PubMed/NCBI
|
13
|
Williams M, Liu ZW, Hunter A and Macbeth
F: An updated systematic review of lung chemo-radiotherapy using a
new evidence aggregation method. Lung Cancer. 87:290–295. 2015.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Cui X, Jin T, Wang X, Jin G, Li Z and Lin
L: NAD(P)H: Quinone oxidoreductase-1 overexpression predicts poor
prognosis in small cell lung cancer. Oncol Rep. 32:2589–2595.
2014.PubMed/NCBI
|
15
|
Huang B, Gao Y, Tian D and Zheng M: A
small interfering ABCE1-targeting RNA inhibits the proliferation
and invasiveness of small cell lung cancer. Int J Mol Med.
25:687–693. 2010.PubMed/NCBI
|
16
|
Li S, Wang H, Hong L, Liu W, Huang F, Wang
J, Wang P, Zhang X and Zhou J: Cryptotanshinone inhibits breast
cancer cell growth by suppressing estrogen receptor signaling.
Cancer Biol Ther. 16:176–184. 2015. View Article : Google Scholar : PubMed/NCBI
|
17
|
Yu HJ, Park C, Kim SJ, Cho NP and Cho SD:
Signal transducer and activators of transcription 3 regulates
cryptotanshinone-induced apoptosis in human mucoepidermoid
carcinoma cells. Pharmacogn Mag. 10(Suppl 3): S622–S629.
2014.PubMed/NCBI
|
18
|
Park IJ, Yang WK, Nam SH, Hong J, Yang KR,
Kim J, Kim SS, Choe W, Kang I and Ha J: Cryptotanshinone induces G1
cell cycle arrest and autophagic cell death by activating the
AMP-activated protein kinase signal pathway in HepG2 hepatoma.
Apoptosis. 19:615–628. 2014. View Article : Google Scholar : PubMed/NCBI
|
19
|
Zikos TA, Donnenberg AD, Landreneau RJ,
Luketich JD and Donnenberg VS: Lung T-cell subset composition at
the time of surgical resection is a prognostic indicator in
non-small cell lung cancer. Cancer Immunol Immunother. 60:819–827.
2011. View Article : Google Scholar : PubMed/NCBI
|
20
|
Que Z, Zou F, Zhang A, Zheng Y, Bi L,
Zhong J, Tian J and Liu J: Ganoderic acid Me induces the apoptosis
of competent T cells and increases the proportion of Treg cells
through enhancing the expression and activation of indoleamine
2,3-dioxygenase in mouse lewis lung cancer cells. Int
Immunopharmacol. 23:192–204. 2014. View Article : Google Scholar : PubMed/NCBI
|
21
|
Pircher A, Gamerith G, Amann A, Reinold S,
Popper H, Gächter A, Pall G, Wöll E, Jamnig H, Gastl G, et al:
Neoadjuvant chemo-immunotherapy modifies CD4(+)CD25(+) regulatory T
cells (Treg) in non-small cell lung cancer (NSCLC) patients. Lung
Cancer. 85:81–87. 2014. View Article : Google Scholar : PubMed/NCBI
|
22
|
Grzesk E, Koltan S, Debski R, Wysocki M,
Gruszka M, Kubicka M, Kołtan A, Grześk G, Manysiak S and
Odrowąż-Sypniewska G: Concentrations of IL-15, IL-18, IFN-γ and
activity of CD4, CD8 and NK cells at admission in children with
viral bronchiolitis. Exp Ther Med. 1:873–877. 2010.PubMed/NCBI
|
23
|
Zhou J, Xu XZ, Hu YR, Hu AR, Zhu CL and
Gao GS: Cryptotanshinone induces inhibition of breast tumor growth
by cytotoxic CD4+ T cells through the
JAK2/STAT4/perforin pathway. Asian Pac J Cancer Prev. 15:2439–2445.
2014. View Article : Google Scholar : PubMed/NCBI
|
24
|
Hu Y, Hong Y, Xu Y, Liu P, Guo DH and Chen
Y: Inhibition of the JAK/STAT pathway with ruxolitinib overcomes
cisplatin resistance in non-small-cell lung cancer NSCLC.
Apoptosis. 19:1627–1636. 2014. View Article : Google Scholar : PubMed/NCBI
|
25
|
Gurbuz V, Konac E, Varol N, Yilmaz A,
Gurocak S, Menevse S and Sozen S: Effects of AG490 and S3I-201 on
regulation of the JAK/STAT3 signaling pathway in relation to
angiogenesis in TRAIL-resistant prostate cancer cells in vitro.
Oncol Lett. 7:755–763. 2014.PubMed/NCBI
|
26
|
Jo SK, Hong JY, Park HJ and Lee SK:
Anticancer activity of novel Daphnane Diterpenoids from Daphne
genkwa through cell-cycle arrest and suppression of Akt/STAT/Src
signalings in human lung cancer cells. Biomol Ther (Seoul).
20:513–519. 2012. View Article : Google Scholar : PubMed/NCBI
|
27
|
Sun W, Ma Y, Chen P and Wang D:
MicroRNA-10a silencing reverses cisplatin resistance in the
A549/cisplatin human lung cancer cell line via the transforming
growth factor-β/Smad2/STAT3/STAT5 pathway. Mol Med Rep.
11:3854–3859. 2015.PubMed/NCBI
|
28
|
Jung JH, Kwon TR, Jeong SJ, Kim EO, Sohn
EJ, Yun M and Kim SH: Apoptosis induced by tanshinone IIa and
cryptotanshinone is mediated by distinct JAK/STAT3/5 and SHP1/2
signaling in chronic myeloid leukemia K562 cells. Evid Based
Complement Alternat Med. 2013:8056392013. View Article : Google Scholar : PubMed/NCBI
|
29
|
Shin DS, Kim HN, Shin KD, Yoon YJ, Kim SJ,
Han DC and Kwon BM: Cryptotanshinone inhibits constitutive signal
transducer and activator of transcription 3 function through
blocking the dimerization in DU145 prostate cancer cells. Cancer
Res. 69:193–202. 2009. View Article : Google Scholar : PubMed/NCBI
|